TSL

Open App

Novo Nordisk After Wegovy: Can Five New Blockbusters Restart the Growth Story?

Educational research only — not investment advice.

Novo Nordisk stock is entering an important transition.

Wegovy and Ozempic turned Novo into one of the world’s largest pharmaceutical companies.

Now investors want to know:

What comes after semaglutide?

Novo says it aims to launch more than five major blockbuster medicines by 2030 and generate over 150 billion Danish kroner of pipeline sales by 2035.

Why Novo Needs New Growth

Wegovy still has enormous demand.

But Novo faces three major pressures:

  • stronger competition from Eli Lilly
  • lower drug prices
  • eventual semaglutide patent expirations

Eli Lilly’s Zepbound has gained market share quickly, while Novo investors are increasingly questioning whether obesity drugs alone can support long-term growth.

That means Novo needs a broader pipeline.

What Comes After Wegovy?

Novo is developing several next-generation medicines.

One of the most important is CagriSema, a combination obesity treatment designed to produce greater weight loss than existing therapies.

Another is zenagamtide, alongside several oral obesity treatments.

Novo also plans to have at least five Phase 3 programs in obesity and diabetes and another five in other therapeutic areas by 2030.

The company is therefore trying to move from:

one dominant franchise

to

multiple large growth products.

Weight-Loss Pills Could Be Huge

Novo’s CEO believes pills could eventually represent around 50% of the obesity-drug market by 2030.

That matters because pills are easier to distribute and may appeal to patients who dislike injections.

Novo already has oral Wegovy in the U.S. and is developing several additional pills.

If oral treatments expand the overall obesity market, Novo could reach millions of new patients.

But Competition Is Getting Harder

Novo is no longer competing only with Eli Lilly.

Roche, Pfizer, Amgen, AstraZeneca and several biotech companies are also developing weight-loss medicines.

More competition can mean:

lower prices + higher marketing costs + less market share

So even if the obesity market reaches $100 billion or more, Novo may capture a smaller percentage of it.

Why Investors Are Still Cautious

Novo shares fell sharply during its latest Capital Markets Day despite the company’s long-term targets.

Investors questioned pricing, M&A strategy and whether the pipeline can replace future semaglutide sales.

That highlights an important difference:

a promising pipeline is not the same as proven revenue.

Drug trials can fail.

Approvals can be delayed.

Competitors can launch better products.

What Should Investors Watch?

Watch Wegovy sales, CagriSema results, oral obesity drugs, Eli Lilly competition and new pipeline launches.

The central question is:

Can Novo turn today’s obesity leadership into several new blockbuster franchises before Wegovy’s growth slows?

If it succeeds, Novo could restart a broader growth story.

If not, investors may continue questioning how much of today’s valuation depends on one extraordinarily successful drug family.

Track Pharma Trends With TradingSimuLab

TradingSimuLab’s Trend Detector and Risk tools help users study changing sector momentum, market trends and risk conditions.

For more quantitative market research and educational trading tools, sign up to TradingSimuLab.

TradingSimuLab is for educational and research purposes only and does not provide investment advice.

MORE INSIGHTS

Continue exploring TradingSimuLab.

  • Codelco Restructuring: Can the World’s Copper Giant Reverse Years of Falling Production?

    Codelco Restructuring: Can the World’s Copper Giant Reverse Years of Falling Production? Educational research only — not investment advice. Codelco copper production has become one of the biggest issues in the global metals market. Chile’s state-owned mining giant is preparing a major restructuring after years of weak production, rising costs and operational problems. That matters…

  • Petrobras Diesel Subsidy Explained: Can Brazil Keep Fuel Prices Below Global Levels?

    Educational research only — not investment advice. Petrobras stock is facing an unusual fuel-market problem. Global diesel prices have surged, but Petrobras has kept Brazilian diesel much cheaper than international import prices. The gap recently reached about 3.89 reais per liter, the widest on record. That sounds good for consumers. But it creates a bigger…

  • Brazil Cuts Rates Again: Can the Selic Fall Without Reigniting Inflation?

    Educational research only — not investment advice. Brazil interest rates are falling again. Brazil’s central bank cut the Selic rate to 13.75%, its fifth consecutive reduction. But 13.75% is still extremely high. That leaves policymakers with a difficult question: How quickly can Brazil cut rates without bringing inflation back? Why Is Brazil Cutting Rates? The…

  • Mexico’s AI Manufacturing Boom: Why Industrial REITs Could Be a Hidden Winner

    Educational research only — not investment advice. Mexico REITs could become an overlooked way to benefit from the AI and North American manufacturing boom. Mexico may not produce most of the world’s advanced AI chips, but it increasingly provides the factories, warehouses and logistics infrastructure behind technology supply chains. That could benefit Mexican real-estate trusts…

  • U.S.–Mexico Trade Deal: What Lower Auto, Steel and Aluminum Tariffs Could Mean for Mexican Stocks

    Educational research only — not investment advice. Mexico stocks could become increasingly sensitive to progress in U.S.–Mexico trade negotiations. Mexico says discussions with Washington are advancing, with tariffs on cars, steel and aluminum among the biggest issues. The potential market impact is simple: lower tariffs → cheaper exports → stronger manufacturing → less uncertainty for…

  • America’s EV Factory Boom Is Reversing: What Happened to the Battery Belt?

    Educational research only — not investment advice. EV stocks were once backed by a huge U.S. factory-building boom. Automakers and battery companies announced billions of dollars of new plants across states including Georgia, Kentucky, Tennessee, Ohio and Indiana. The region became known as the Battery Belt. Now many of those projects are being delayed, reduced…

  • The Yield Curve Is Warning About Consumers: Can Households Handle Higher Rates?

    Educational research only — not investment advice. The yield curve today is sending an important message about the U.S. consumer. Short-term Treasury yields remain high as the Federal Reserve fights inflation, while longer-term yields suggest investors are increasingly thinking about what those higher borrowing costs could eventually do to economic growth. The concern is simple:…

  • Currency Risk Is Rising: Why U.S. Companies AreHedging Less Despite a Volatile Dollar

    Educational research only — not investment advice. Currency hedging is becoming less common at a surprisingly risky time. U.S. and UK companies reduced their foreign-exchange protection sharply in the second quarter of 2026. The average hedge ratio fell from 57% to 46%, while the average hedge period dropped to just 5.7 months. That means companies…

  • Investors Buy U.S. Stocks but Sell Corporate Bonds: What Is the Market Telling Us?

    Educational research only — not investment advice. US stock market flows are sending an unusual message. Investors recently bought U.S. equities at their fastest pace in three months while simultaneously taking money out of corporate bonds. Bank of America data showed $63.8 billion flowing into U.S. stocks in one week. At the same time, investors…

TRADINGSIMULAB

Continue your market research with TradingSimuLab.

Explore TradingSimuLab’s five-model research framework, watchlist and tools for trend, timing, macro and risk analysis.

Open app